Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9717740 | ETON | Treatment of adrenal insufficiency |
Nov, 2032
(8 years from now) | |
US9675559 | ETON | Treatment of adrenal insufficiency |
Jan, 2033
(8 years from now) | |
US9649280 | ETON | Composition comprising hydrocortisone |
May, 2034
(10 years from now) |
Alkindi Sprinkle is owned by Eton.
Alkindi Sprinkle contains Hydrocortisone.
Alkindi Sprinkle has a total of 3 drug patents out of which 0 drug patents have expired.
Alkindi Sprinkle was authorised for market use on 29 September, 2020.
Alkindi Sprinkle is available in granule;oral dosage forms.
Alkindi Sprinkle can be used as treatment of adrenal insufficiency.
The generics of Alkindi Sprinkle are possible to be released after 12 May, 2034.
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL